Haval Shirwan Selected Research

Member 9 Tumor Necrosis Factor Receptor Superfamily

1/2019	A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells.
1/2012	SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
5/2010	4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haval Shirwan Research Topics

Disease

27	Neoplasms (Cancer) 03/2021 - 07/2003
8	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2022 - 03/2006
5	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2019 - 07/2007
4	Carcinoma (Carcinomatosis) 01/2013 - 05/2009
3	Inflammation (Inflammations) 01/2017 - 08/2013
3	Persistent Infection 08/2010 - 12/2009
2	Plague (Bubonic Plague) 10/2019 - 09/2014
2	Infections 01/2017 - 09/2014
1	Hemorrhage 01/2022
1	Cicatrix (Scar) 01/2017
1	Lewis Lung Carcinoma 11/2014
1	Neoplasm Metastasis (Metastasis) 11/2014
1	Sleep Deprivation 03/2014
1	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2013
1	Hyperglycemia 08/2013
1	Splenomegaly 12/2009
1	Hepatitis 12/2009
1	Enterobiasis 03/2006
1	Parasitic Diseases (Parasitic Disease) 03/2006

Drug/Important Bio-Agent (IBA)

13	VaccinesIBA 10/2019 - 05/2009
11	AntigensIBA 01/2019 - 07/2007
9	Proteins (Proteins, Gene)FDA Link 11/2014 - 03/2006
5	Subunit VaccinesIBA 10/2019 - 05/2010
5	SurvivinIBA 11/2014 - 05/2009
4	LigandsIBA 01/2019 - 06/2009
4	Cancer VaccinesIBA 01/2018 - 12/2007
3	Insulin (Novolin)FDA Link 11/2022 - 04/2007
3	Therapeutic UsesIBA 01/2019 - 06/2007
3	Immunologic Factors (Immunomodulators)IBA 01/2019 - 06/2009
3	Member 9 Tumor Necrosis Factor Receptor SuperfamilyIBA 01/2019 - 05/2010
3	Fas Ligand Protein (Fas Ligand)IBA 01/2017 - 08/2013
2	Recombinant ProteinsIBA 01/2019 - 08/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2014
2	Biocompatible Materials (Biomaterials)IBA 01/2017 - 01/2017
2	Oncogene Proteins (Oncogene Protein)IBA 08/2010 - 05/2010
2	CytokinesIBA 08/2010 - 12/2009
2	Peptides (Polypeptides)IBA 05/2009 - 07/2007
2	StreptavidinIBA 04/2007 - 03/2006
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Biological Warfare AgentsIBA 10/2019
1	Aluminum Hydroxide (Algeldrate)FDA Link 10/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	A-Form DNA (A-DNA)IBA 01/2019
1	CollagenIBA 01/2019
1	AntibodiesIBA 01/2019
1	Alkylating AgentsIBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2018
1	HydrogelsIBA 01/2017
1	aluminum sulfate (alum)IBA 09/2014
1	Recombinant Fusion ProteinsIBA 09/2014
1	Capsules (Microcapsules)IBA 03/2014
1	Blood Glucose (Blood Sugar)IBA 08/2013
1	Viral AntigensIBA 01/2013
1	AutoantigensIBA 01/2013
1	Conjugate VaccinesIBA 05/2010
1	Toll-Like Receptor AgonistsIBA 05/2009
1	4-1BB Ligand (4 1BB Ligand)IBA 05/2009
1	CalreticulinIBA 07/2007
1	human CALR proteinIBA 07/2007
1	FenbendazoleIBA 03/2006
1	AnthelminticsIBA 03/2006
1	Pharmaceutical PreparationsIBA 03/2006

Therapy/Procedure

12	Immunotherapy 01/2020 - 07/2003
7	Therapeutics 01/2019 - 03/2006
5	Islets of Langerhans Transplantation 01/2022 - 12/2011
1	Operative Surgical Procedures 01/2022
1	Chemoprevention 03/2021
1	Oncolytic Virotherapy 01/2018
1	Autologous Transplantation 01/2017
1	Pancreatectomy 01/2017
1	Immunomodulation 10/2013